Enhancing Chemotherapy of p53‐Mutated Cancer through Ubiquitination‐Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe‐4 Nanoparticles
Authors:
- 17 August 2020
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 30 (40)
Abstract
A significant percentage of human cancers harbor missense mutations in the TP53 gene and express highly stabilized mutant p53 protein (mutp53) with tumor‐promoting gain‐of‐function (GOF) properties. Inducing mutp53 degradation is a viable precision anti‐tumor therapeutic strategy. Based on the previously reported finding that a zinc‐curcumin compound induced mutp53 degradation, a series of ZnFe nanoparticles (ZnFe NPs) are synthesized and it is found that ZnFe‐4, with an Zn:Fe ratio of 1:2, exhibits outstanding mutp53‐degrading capability. ZnFe‐4 induced ubiquitination‐mediated proteasomal degradation of several different mutp53 species, but not the wild‐type p53 protein. Cellular internalization, intracellular Zn++ elevation and increased ROS are all necessary for ZnFe‐4‐induced mutp53 degradation. Degradation of mutp53 by ZnFe‐4, abrogated mutp53‐manifested GOF, leading to increased p21 expression, cell cycle arrest, reduced cell proliferation and cell migration, and cell demise. ZnFe‐4 also sensitized to cisplatin‐elicited killing in p53 S241F ES‐2 ovarian cancer cells, and dramatically improved the therapeutic efficacy of cisplatin in a subcutaneous ES‐2 tumor model. The potential clinical utility of ZnFe‐4 is further demonstrated in an orthotopically‐implanted p53 Y220C patient‐derived xenograft (PDX) breast cancer model. ZnFe‐4 is the first reported mutp53‐degrading nanomaterial, and further materials engineering may lead to the development of zinc‐based nanoparticles with minimal toxicity and maximized mutp53‐degrading capability.Keywords
Funding Information
- National Basic Research Program of China (2017YFA0205600)
- National Natural Science Foundation of China (91859103, 81771975, 31671030)
- Guangdong Provincial Introduction of Innovative Research and Development Team (2017ZT07S054)
This publication has 45 references indexed in Scilit:
- Putting p53 in ContextCell, 2017
- The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic ApproachesAnnual Review of Biochemistry, 2016
- Unravelling mechanisms of p53-mediated tumour suppressionNature Reviews Cancer, 2014
- p53 mutations in cancerNature Cell Biology, 2013
- Allele-Specific p53 Mutant ReactivationCancer Cell, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- Curing Cancer with p53New England Journal of Medicine, 2004
- p53 Mutations in Human CancersScience, 1991